scholarly journals Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 and -2 in Type 2 Diabetes: Effect of 1 year's cardiovascular risk reduction therapy

Diabetes Care ◽  
2004 ◽  
Vol 27 (8) ◽  
pp. 2049-2051 ◽  
Author(s):  
M. H. Tayebjee ◽  
H. S. Lim ◽  
R. J. MacFadyen ◽  
G. Y.H. Lip
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Matrix Metalloproteinase ◽  
Risk Reduction ◽  
Matrix Metalloproteinase 9 ◽  
Tissue Inhibitor Of Metalloproteinase ◽  
Tissue Inhibitor ◽  
Cardiovascular Risk Reduction ◽  
Metalloproteinase 9

Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

2017 ◽  
Vol 31 (4) ◽  
pp. 459-470 ◽  
Author(s):  
Scott L. Purga ◽  
Mandeep Sidhu ◽  
Michael Farkouh ◽  
Joshua Schulman-Marcus
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Cardiovascular Risk Reduction

scholarly journals 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

2020 ◽  
Vol 76 (9) ◽  
pp. 1117-1145 ◽  
Author(s):  
Sandeep R. Das ◽  
Brendan M. Everett ◽  
Kim K. Birtcher ◽  
Jenifer M. Brown ◽  
James L. Januzzi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Expert Consensus ◽  
Novel Therapies ◽  
Cardiovascular Risk Reduction ◽  
Consensus Decision
Sign in / Sign up

Export Citation Format

Share Document